Beta-blocker attenuates cardiotoxicity related anthracycline usage

Lukman Zulkifli Amin, Hilman Zulkifli Amin, Zulkifli Amin

Research output: Contribution to journalReview articlepeer-review


To summarize the recent trials and studies of the role of beta-blocker on the treatment for cancer patients treated with anthracycline to decrease morbidity and mortality rate. Good management of cancer will result in large numbers of cancer survivors. On the other hand, cancer therapy also has side effects, one of which is cardiotoxicity. Cardiotoxicity could reduce therapy effectiveness, hence, increase disease progression and mortality rate. Anthracyclines is one of the chemotherapy agents with cardiotoxicity as a side effect. Beta-blocker has the ability to reduce cardiotoxicity due to anthracyclines usage.

Original languageEnglish
Pages (from-to)1389-1392
Number of pages4
JournalJournal of the Medical Association of Thailand
Issue number8
Publication statusPublished - 2021


  • Anthracyclines
  • Beta-blocker
  • Cardiotoxicity


Dive into the research topics of 'Beta-blocker attenuates cardiotoxicity related anthracycline usage'. Together they form a unique fingerprint.

Cite this